161600-01-7
Chemical Structure
Netoglitazone
Synonym(s): MCC-555; Isaglitazone
- CAS No.: 161600-01-7
- Formula:C21H16FNO3S
- Molecular Weight:381.42
IUPAC Name: 5-((6-((2-fluorobenzyl)oxy)naphthalen-2-yl)methyl)thiazolidine-2,4-dione
InChIKey: PKWDZWYVIHVNKS-UHFFFAOYSA-N
SMILES: O=C(N1)SC(CC2=CC=C3C=C(OCC4=CC=CC=C4F)C=CC3=C2)C1=O
Biological Activity: Netoglitazone (MCC-555) is an orally active PPARγ ligand with an EC50 of 8 μM. Netoglitazone mediates cell type-specific functional regulation, and modulates the transcriptional activity of PPARγ as a full agonist, partial agonist or antagonist. Netoglitazone induces adipogenesis, inhibits osteoblastogenesis, alters the weight of extramedullary fat depots and enhances insulin sensitivity. Netoglitazone reduces blood glucose levels. Netoglitazone can be used in research related to type 2 diabetes and non-insulin-dependent diabetes mellitus[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Netoglitazone | 99.92% | Netoglitazone (MCC-555) is an orally active PPARγ ligand with an EC50 of 8 μM. Netoglitazone mediates cell type-specific functional regulation, and modulates the transcriptional activity of PPARγ as a full agonist, partial agonist or antagonist. Netoglitazone induces adipogenesis, inhibits osteoblastogenesis, alters the weight of extramedullary fat depots and enhances insulin sensitivity. Netoglitazone reduces blood glucose levels. Netoglitazone can be used in research related to type 2 diabetes and non-insulin-dependent diabetes mellitus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Netoglitazone (Standard) | ≥98% | Netoglitazone (Standard) is the analytical standard of Netoglitazone (HY-100428). This product is intended for research and analytical applications. Netoglitazone (MCC-555) is an orally active PPARγ ligand with an EC50 of 8 μM. Netoglitazone mediates cell type-specific functional regulation, and modulates the transcriptional activity of PPARγ as a full agonist, partial agonist or antagonist. Netoglitazone induces adipogenesis, inhibits osteoblastogenesis, alters the weight of extramedullary fat depots and enhances insulin sensitivity. Netoglitazone reduces blood glucose levels. Netoglitazone can be used in research related to type 2 diabetes and non-insulin-dependent diabetes mellitus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lazarenko OP, et al. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 2006;38(1):74-84. [Content Brief]
- [2]. Grey A, et al. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19(2):129-137. [Content Brief]
- [3]. Reginato MJ, et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem. 1998;273(49):32679-32684. [Content Brief]
- [4]. Ramakers JD, et al. The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J Clin Immunol. 2007;27(3):275-283. [Content Brief]
